Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.